FFAR4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6615	0.50	8/20
SCHEMBL8332	0.48	7/20
SCHEMBL14243	0.42	7/20
SCHEMBL6614	0.50	6/20
SCHEMBL8242	0.43	6/20
SCHEMBL47815	0.38	6/20
SCHEMBL5455	0.71	5/20
Phenyl Propionic Acid (SCHEMBL3419)	0.67	5/20
SCHEMBL70972	0.58	5/20
SCHEMBL7260	0.44	5/20
SCHEMBL69746	0.65	4/20
SCHEMBL69089	0.60	4/20
SCHEMBL70271	0.52	4/20
SCHEMBL65140	0.50	4/20
SCHEMBL69559	0.46	4/20
SCHEMBL46690	0.57	3/20
SCHEMBL73828	0.55	3/20
SCHEMBL1509	0.54	3/20
SCHEMBL36574	0.51	3/20
SCHEMBL71453	0.49	3/20

Clinical trials — most relevant to FFAR4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Fat, Inflammation and Insulin Resistance	PHASE4	COMPLETED
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes	PHASE4	COMPLETED
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity	PHASE4	COMPLETED
Niacin, N-3 Fatty Acids and Insulin Resistance	PHASE4	COMPLETED
Omega 3 Supplementation in Fatty Liver	PHASE3	COMPLETED
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome	PHASE2/PHASE3	COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides	PHASE1	COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Colonic Propionate, Appetite, and Weight Loss	nan	COMPLETED
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis	nan	WITHDRAWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Molecular Pathways Related to Short-term Fasting Response	nan	COMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED
Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus	nan	COMPLETED
Growth Hormone Signaling in Vivo in Humans	nan	COMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients	nan	COMPLETED
Study of Changes in Skeletal Muscle After Caloric Restriction	nan	ACTIVE_NOT_RECRUITING
Hepatic Metabolic Changes in Response to Glucagon Infusion	nan	COMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients	nan	COMPLETED
Production of Free Fatty Acids From Blood Triglycerides	nan	COMPLETED
The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity	nan	COMPLETED
FFA Hypertension and Inflammation in Lean and Obese Subjects	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FFAR4 binder may also engage these)

Protein	Name	Similarity
C8YUV0	—	1.000	C8YUV0 →
Q7TMA4	—	1.000	Q7TMA4 →
Q2AC31	—	0.995	Q2AC31 →
Q864K7	—	0.974	Q864K7 →
Q9Y5Y3	—	0.974	Q9Y5Y3 →
P56448	—	0.973	P56448 →
P11617	—	0.972	P11617 →
Q6A155	—	0.972	Q6A155 →
P31392	—	0.972	P31392 →
Q864I2	—	0.971	Q864I2 →
O19037	—	0.971	O19037 →
P43142	—	0.970	P43142 →
P97639	—	0.969	P97639 →
Q91178	—	0.969	Q91178 →
Q864K9	—	0.969	Q864K9 →
Q8BGE9	—	0.969	Q8BGE9 →
Q7TQP3	—	0.968	Q7TQP3 →
Q9EQQ4	—	0.968	Q9EQQ4 →
Q864J6	—	0.968	Q864J6 →
Q864K6	—	0.968	Q864K6 →
Q864K4	—	0.968	Q864K4 →
Q864K5	—	0.968	Q864K5 →
Q864K8	—	0.968	Q864K8 →
Q864F5	—	0.968	Q864F5 →
Q864F4	—	0.968	Q864F4 →
GPR119	Glucose-dependent insulinotropic receptor	0.967	landscape →
Q864K0	—	0.967	Q864K0 →
Q8MJ89	—	0.967	Q8MJ89 →
Q864L0	—	0.967	Q864L0 →
Q864F8	—	0.966	Q864F8 →